文献速递骨质疏松与代谢性骨病

长期地舒单抗治疗停药后的观察性研究

Observations following discontinuation of long-term denosumab therapy.
PubMed 文献 · Osteoporos Int · 2017-01-31

这项1年观察性研究纳入完成2期研究中最多8年地舒单抗治疗的138例合格患者中的82例,大多数(65例,79%)未接受处方骨质疏松药物,接受地舒单抗8年的52例患者腰椎和全髋骨密度分别下降6.7%和6.6%,接受骨质疏松药物治疗者骨密度下降幅度较小,8例(9.8%)患者发生17次骨折。

要点

  • 停用地舒单抗后1年内腰椎和全髋骨密度分别下降6.7%和6.6%。
  • 观察期间使用骨质疏松药物者骨密度下降幅度小于未使用者。
  • 8例(9.8%)患者发生17次骨折,均有至少一项易感危险因素。

核心结论

  • 停药导致地舒单抗对骨密度的影响逆转,可能也影响骨折风险,这与地舒单抗的作用机制一致。
  • 对于接受骨质疏松治疗的患者,骨丢失被减弱。
  • 对于骨折高风险患者,若停用地舒单抗,换用另一种骨质疏松治疗似乎是合适的。

研究设计与样本

  • 本研究为2期研究中最多8年地舒单抗治疗后的1年观察性随访研究。
  • 观察年内患者由医生酌情进行骨质疏松管理,返回诊所进行骨密度评估并完成骨质疏松管理问卷。
  • 收集严重不良事件和骨折的发生情况,分析为描述性。
  • 138例合格患者中82例入组并完成观察研究。

主要发现

  • 大多数患者(65例,79%)未接受处方骨质疏松药物,最常见原因(23例,35%)为「我的医生认为我不再需要药物」。
  • 17例服用骨质疏松药物的患者中,8例在观察研究期间停药。
  • 接受地舒单抗治疗8年的患者(N=52)在1年观察研究期间骨密度下降:腰椎6.7%,全髋6.6%。
  • 观察研究期间服用骨质疏松药物者骨密度下降幅度小于未服用者。
  • 未发现新的安全性问题。

临床怎么用

  • 作者认为,对于骨折高风险患者,若停用地舒单抗,换用另一种骨质疏松治疗似乎是合适的。
  • 停用地舒单抗时应考虑采取治疗以预防骨丢失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Stopping denosumab after 8 years of continued treatment was associated with bone loss during a 1-year observation study in patients who were not prescribed osteoporosis treatment. Bone loss was attenuated in patients who began another osteoporosis therapy. Treatment to prevent bone loss upon stopping denosumab should be considered. INTRODUCTION: This study aimed to understand osteoporosis management strategies during a 1-year observational follow-up after up to 8 years of denosumab treatment in a phase 2 study. METHODS: During the observational year, patients received osteoporosis management at the discretion of their physician and returned to the clinic for BMD assessment and completion of an osteoporosis management questionnaire. Incidence of serious adverse events and fractures was collected. Analyses were descriptive. RESULTS: Of 138 eligible patients, 82 enrolled in and completed the observation study. Most (65 [79%]) did not receive prescription osteoporosis medication, with "my doctor felt I no longer needed a medication" being the most common reason (23 [35%]). Of the 17 patients who took osteoporosis medications, 8 discontinued therapy during the observation study. In patients treated with denosumab for 8 years (N = 52), BMD decreased during the 1-year observation study (6.7% [lumbar spine], 6.6% [total hip]). Those who took osteoporosis medication during the observation study showed a smaller decline in BMD than those who did not. No new safety concerns were identified. Eight patients (9.8%), all of whom had at least one predisposing risk factor, experienced 17 fractures. This included seven patients who experienced one or more vertebral fractures. CONCLUSIONS: Consistent with denosumab's mechanism of action, treatment cessation led to reversal of the drug's effect on BMD and perhaps fracture risk. For patients who took osteoporosis therapy, bone loss was attenuated. For patients at high fracture risk, switching to another osteoporosis therapy if denosumab is discontinued seems appropriate.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. McClung MR, Wagman RB, Miller PD, et al. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 2017. PMID: 28144701. doi:10.1007/s00198-017-3919-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。